Risk factors for development of heart failure

Current Cardiology Reviews

Volumn 3, Issue 1, 2007, Pages 1-9

  Listerman, Jennifer ^a   Huang, Robert L ^a,b   Geisberg, Carrie ^a   Butler, Javed ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b VA National Quality Scholars Program   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Diabetes; Heart failure; Hypertension; Myocardial infarction; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA 2C ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CAFFEINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DOXAZOSIN; DOXORUBICIN; HOMOCYSTEINE; INTERLEUKIN 6; NATRIURETIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; AGING; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG EXPOSURE; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; GENDER; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC MARKER; GEOGRAPHIC DISTRIBUTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LIFESTYLE; LUNG DISEASE; MALE; MORBIDITY; MORTALITY; OBESITY; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP APNEA SYNDROME; SOCIOECONOMICS; SODIUM INTAKE; STRESS; SURVIVAL RATE; TACHYCARDIA; UNITED STATES; VALVULAR HEART DISEASE;

EID: 33847281330     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340307779939916     Document Type: Review

References (125)

1. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88(1): 107-15.
2. Schocken DD, Arrieta MI, Leaverton PE, and Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20(2): 301-6.
3. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure: rationale and design. Am Heart J 2004; 148(1): 43-51.
4. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-6.
5. Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 1992; 13: 588-93.
6. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
7. Kimmelstiel CD, Konstam MA. Heart failure in women. Cardiology 1995; 86: 304-9.
8. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-9.
9. Chae CU, Pfeffer MA, Glynn RJ, et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999; 281: 634-43.
10. Chen YT, Vaccarino V, Williams CS, et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999; 106: 605-12.
11. Gottdiener JS, Arnold AM, Aurigemma GP et al. Predictors of heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-37.
12. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161: 996-1002.
13. Hypertension Detection and Follow-up Program Cooperative Group. Educational level and 5-year all-cause mortality in the Hypertension Detection and Follow-up Program. Hypertension 1987; 9: 641-6.
14. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between socioeconomic status and diabetes control and complications in the EURO DIAB IDDM Complications Study. Diabetes Care 1996; 19: 423-30.
15. Karch SB. Billingham ME. The pathology and etiology of cocaine-induced heart disease. Arch Pathology Lab Med 1988; 112: 225-30.
16. Goldenberg SP. Zeldis SM. Fatal acute congestive heart failure in a patient with idiopathic hemochromatosis and cocaine use. Chest. 1987; 92: 374-5.
17. O'Keefe DD. Grantham RN. Beierholm EA. et al. Cocaine and the contractile response to catecholamines in right ventricular failure. Am J Physiology 1977; 233: H399-403.
18. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med 2001; 249: 253-61.
19. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-30.
20. Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis 2003; 46: 79-90.
21. Gvozdjakova A, Kucharska J, Gvozdjak J. Effect of smoking on the oxidative processes of cardiomyocytes. Cardiology 1992; 81: 81-4.
22. Michael PR. Cigarette smoking, endothelial injury and cardio-vascular disease. Int J Exp Pathol 2000; 81: 219-30.
23. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320: 409-15.
24. Rubin E, Urbano-Marquez A. Alcoholic cardiomyopathy. Alcohol Clin Exp Res 1994; 18: 111-4.
25. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA 2001; 285: 1971-7.
26. Marmot MG, Elliott P, Shipley MJ, et al. Alcohol and blood pressure: the INTERSALT study. BMJ 1994; 308: 1263-7.
27. Gillman MW, Cook NR, Evans DA, et al. Relationship of alcohol intake with blood pressure in young adults. Hypertension 1995; 25: 1106-10.
28. Lee WK, Regan TJ. Alcoholic cardiomyopathy: is it dose-dependent? Congest Heart Fail 2002; 8: 303-6.
29. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2002; 136: 181-91.
30. Ajani UA, Hennekens CH, Spelsberg A, et al. Alcohol consumption and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med 2000; 160: 1025-30.
31. Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993; 329: 1829-34.
32. Camargo CA Jr, Stampfer MJ, Glynn RJ et al. Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in US male physicians. Ann Intern Med 1997; 126: 372-5.
33. Rubin R. Effect of ethanol on platelet function. Alcohol Cli Exp Res 1999; 23: 1114-8.
34. Ridker PM, Vaughan DE, Stampfer MJ, et al. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA 1994; 272: 929-33.
35. He J, Ogden LG, Bazzano LA, et al. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: 1st National Health and Nutrition Examination Survey epidemiologic follow-up study. Arch Intern Med 2002; 162: 1619-24.
36. Sugimoto K, Fujimura A, Takasaki I, et al. Effects of reninangiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats. Hypertens Res 1998; 21: 163-8.
37. Kupari M, Koskinen P, Virolainen J. Correlates of left ventricular mass in a population. Focus on lifestyle and salt intake. Circulation 1994; 89: 1041-50.
38. Schmieder RE, Messerli FH, Garavaglia GE, et al. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation 1988; 78: 951-6.
39. Langenfeld MR, Schobel H, Veelken R, et al. Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. Eur Heart J 1998; 19: 951-8.
40. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161-72.
41. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.
42. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003; 138: 10-6.
43. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36: 130-8.
44. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992; 327: 998-1008.
45. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996; 156: 1789-96.
46. Frohlich ED. State of the art lecture. Risk mechanisms in hypertensive heart disease. Hypertension 1999; 34: 782-9.
47. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-45.
48. Davis BR, Cutler JA, Furberg CD, et al. Relationship of anti-hypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the ALLHAT Trial. Ann Intern Med 2002; 137: 313-20.
49. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 1987; 10 (Suppl 6): S 135-40.
50. Beache GM, Herzka DA, Boxerman JL, et al Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation 2001; 104: 1214-7.
51. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970; 72: 813-22.
52. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987; 75:I19-25.
53. Kenchaiah S, Pfeffer MA. Cardiac remodeling in systemic hypertension. Med Clin N Am 2004; 88: 115-30.
54. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34.
55. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77: 1017-20.
56. Bonow RO, Mitch WE, Nesto RW, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group V: management of cardiovascular-renal complications. Circulation 2002; 105: e159-64.
57. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-73.
58. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13.
59. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72: S3-9.
60. Schillaci G, Vaudo G, Reboldi G, et al High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 2001; 19: 2265-70.
61. Horio T, Miyazato J, Kamide K, et al. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 2003; 16: 938-44.
62. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3: 249-54.
63. Mansfield DR, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004; 169: 361-6.
64. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: 1364-72.
65. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681-9.
66. Mourad JJ, Girerd X, Boutouyrie P, et al. Increased stiffness of radial artery wall material in end-stage renal disease. Hypertension 1997; 30: 1425-30.
67. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-10.
68. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circ 2003; 107: 87-92.
69. Herbelin A, Urena P, Nguyen AT, et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954-60.
70. Kannel WB, D'Agostino RB, Silbershatz H, et al Profile for estimating risk of heart failure. Arch Intern Med 1999; 159: 1197-204.
71. Carabello B, Crawford FA Jr. Valvular heart disease. N Engl J Med 1997; 337: 32-41.
72. Bonow RO, Carabello B, de Leon AC, et al. Guidelines for the management of patients with valvular heart disease: executive summary. Circ 1998; 98: 1949-84.
73. Chaudhary BA, Ferguson DS, Speir WA Jr. Pulmonary edema as a presenting feature of sleep apnea syndrome. Chest 1982; 82: 122-4.
74. Fletcher EC, Proctor M, Yu J, et al. Pulmonary edema develops after recurrent obstructive apneas. Am J Respir Crit Care Med 1999; 160: 1688-96.
75. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
76. Mcevoy RD. Obstructive sleep apnea and heart failure: two unhappy bedfellows. Am J Respir Crit Care Med 2004; 169: 329-31.
77. Hedner JA, Wilcox I, Laks L, et al. A specific and potent pressor effect of hypoxia in patients with sleep apnea. Am Rev Respir Dis 1992; 146: 1240-5.
78. Sajkov D, Wang T, Saunders NA, et al. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2002; 165: 152-8.
79. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-84.
80. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003; 348: 1233-41.
81. Kannel WB, Seidman JM, Fercho W, Castelli WP. Vital capacity and congestive heart failure. Circulation 1974; 49: 1160-6.
82. Marcus EB, Curb JD, MacLean CJ, et al. Pulmonary function as a predictor of coronary heart disease. Am J Epidemiol 1989; 129: 97-104.
83. Enright PL, Kronmal RA, Smith VE, et al. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. Chest 1995; 107: 28-35.
84. Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med 2001; 161: 1725-30.
85. Williams SA, Kasl SV, Heiat A, et al. Depression and risk of heart failure among the elderly: a prospective community-based study. Psychosom Med 2002; 64: 6-12.
86. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-7.
87. Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994; 51: 411-22.
88. Rozanski A, Bairey CN, Krantz DS, et al. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. N Engl J Med 1988; 318: 1005-12.
89. Pasic J, Levy WC, Sullivan MD. Cytokines in depression and heart failure. Psychosom Med 2003; 65: 181-93.
90. Perlman LV, Ferguson S, Bergum K, et al. Precipitation of congestive heart failure: social and emotional factors. Ann Intern Med 1971; 75: 1-7.
91. Lee BH, Goodenday LS, Muswick GJ, et al. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987; 9: 184-8.
92. Nousiainen T, Vanninen E, Jantunen E, et al. Concomitant impairment of left ventricular systolic and diastolic function during doxorubicin therapy: a prospective radionuclide ventriculographic and echocardiographic study. Leuk Lymphoma 2002; 43: 1807-11.
93. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-79.
94. Gottlieb SL, Edmiston WA Jr, Haywood LJ. Late doxorubicin cardiotoxicity. Chest 1980; 78: 880-2.
95. Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with increased risk of heart failure in elderly patients on diuretics. Arch Intern Med 1998; 158: 1108-12.
96. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under recognized public health problem. Arch Intern Med 2000; 160: 777-84.
97. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure. Circulation 2005; 111: 583-590.
98. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals JAMA 2001; 286: 421-6.
99. Dell'Omo G, Giorgi D, Di Bello V, et al. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men. J Intern Med 2003; 254: 76-84.
100. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-8.
101. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.
102. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for heart failure in adults without prior myocardial infarction. JAMA 2003; 289: 125 1-7.
103. Loscalzo J. The oxidant stress of hyperhomocystinemia. J Clin Invest 1996; 98: 5-7.
104. Blacher J, Demuth K, Guerin AP, et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 1999; 12: 248-55.
105. Symons JD, Multick AE, Ensunsa JL, et al. Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol 2002; 22: 772-80.
106. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
107. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-95.
108. Baumgarten G, Knuefermann P, Mann DL. Cytokines as emerging targets in the treatment of heart failure. Trends Cardiovasc Med 2000; 10: 216-23.
109. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107: 1486-91.
110. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signaltransducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995; 92: 4862-6.
111. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
112. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-12.
113. Welch S, Plank D, Witt S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing mice. Circ Res 2002; 90: 641-8.
114. Wang L, Ma W, Markovich R, et al. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998; 83: 516-22.
115. Vecchione C, Colella S, Fratta L, et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension 2001; 37: 1480-5.
116. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003; 139: 642-8.
117. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.
118. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.
119. Brunner F, Wolkart G. Relaxant effect of C-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature. Cardiovasc Res 2001; 51: 577-84.
120. Vasan RS, Larson MG, Benjamin EJ, et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997; 336: 1350-5.
121. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003; 108: 977-82.
122. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001; 37: 1042-8.
123. Small KM, Wagoner LE, Levin AM, et al Synergistic polymorphisms of beta 1 - and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-42.
124. Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004; 10: 248-54.
125. Benetos A, Gautier S, Ricard S, et al Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996; 94: 698-703.